Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516874 | 1.00 | TDP1 (0.48) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL29733565 | 1.00 | TDP1 (0.48) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL4813848 | 0.98 | TDP1 (0.47) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL29673261 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL1489599 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL424471 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL697038 | 0.93 | TDP1 (0.55) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL9529895 | 0.91 | TDP1 (0.53) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| Water SCHEMBL8461991 | 0.91 | TDP1 (0.53) | TDP1RAB9ANPC1ADRB2ADRB1 | |
| SCHEMBL28794540 | 0.84 | ALOX15 (0.45) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330893-A | Resolution method of nitrogen heterocyclic derivative | 南京正大天晴制药有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-114763339-A | Process for the preparation of triazine derivatives | 江苏恒瑞医药股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| CN-119569739-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569741-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569740-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119330893-A | Resolution method of nitrogen heterocyclic derivative | 南京正大天晴制药有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-114763339-A | Process for the preparation of triazine derivatives | 江苏恒瑞医药股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113214270-A | Compounds and derivatives thereof as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-108137590-B | Spiro (3H-indol-3, 2' -pyrrolidin) -2(1H) -one compounds and their derivatives as MDM2-P53 inhibitors | 勃林格殷格翰国际有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-8637522-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PAATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, IAPP, INSR | TDP1 4595/4885RAB9A 2898/4885NPC1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.